442
Participants
Start Date
February 28, 2013
Primary Completion Date
July 31, 2016
Study Completion Date
October 31, 2016
blisibimod
blisibimod administered via subcutaneous injection every week for 52 weeks
Placebo
Placebo will be administered weekly via subcutaneous injection for 52 weeks
Investigator Site 453, Taipei
Investigator Site 451, Taipei
Investigator Site 402, Ermita, Manila
Investigator Site 408, Cruz Manila
Investigator Site 403, Manila
Investigator Site 401, Las Piñas
Investigator Site 407, Angeles
Investigator Site 410, Iloilo City
Investigator Site 404, Cebu City
Investigator Site 406, Cebu City
Investigator Site 405, Davao City
Investigator Site 201, Ratchathewi
Investigator Site 205, Bangkok Noi
Investigator Site 701, Mexico City
Investigator Site 702, Guanajuato City
Investigator Site 202, Khon Kaen
Investigator Site 455, Taichung
Investigator Site 707, Toluca
Investigator Site 204, Muang Chiang Mai
Investigator Site 452, Kaohsiung City
Investigator Site 704, Mexico City
Investigator Site 705, Yucatán
Investigator Site 101, Singapore
Investigator Site 057, Petrozavodsk
Investigator Site 056, Saint Petersburg
Investigator Site 602, Vitebsk
Investigator Site 061, Smolensk
Investigator Site 604, Minsk
Investigator Site 601, Minsk
Investigator Site 605, Minsk
Investigator Site 603, Homyel
Investigator Site 054, Kursk
Investigator Site 503, Ahmedabad
Investiagtor Site 513, Mumbai
Investigator Site 510, Pune
Investigator Site 062, Orenburg
Investigator Site 508, Bangalore
Investigator Site 060, Vladimir
Investigator Site 055, Yekaterinburg
Investigator Site 058, Novosibirsk
Investigator Site 052, Kemerovo
Investigator Site 053, Kemerovo
Investigator Site 501, Kolkata
Investigator Site 558, Curitiba
Investigator Site 559, Santo André
Investigator Site 302, Antioquia
Investigator Site 303, Antioquia
Investigator Site 308, Atlántico
Investigator Site 310, Atlántico
Investigator Site 301, Bogotá
Investigator Site 311, Bogotá
Investigator Site 304, Cundinamarca
Investigator Site 305, Santander
Investigator Site 306, Santander
Investigator Site 312, Valle
Investigator Site 903, Guatemala City
Investigator Site 904, Guatemala City
Investigator Site 151, Pokfulam
Investigator Site 152, Tuenmen
Investigator Site 251, Kuala Selangor
Investigator Site 252, Perak
Investigator Site 409, Manila
Investigator Site 051, Moscow
Investigator Site 059, Omsk
Investigator Site 355, Daegu
Investigator Site 801, Colombo
Investigator Site 804, Kandy
Investigator Site 802, Nugegoda
Investigator Site 454, Taichung
Investigator Site 555, Goiânia
Investigator Site 557, Juiz de Fora
Investigator Site 551, Porto Alegre
Investigator Site 554, São Paulo
Investigator Site 556, São Paulo
Investigator Site 001, Tbilisi
Investigator Site 002, Tbilisi
Investigator Site 003, Tbilisi
Investigator Site 901, Guatemala City
Investigator Site 902, Guatemala City
Investigator Site 505, Hyderabad
Investigator Site 502, Hyderabad
Investigator Site 506, Manipal
Investigator Site 511, New Delhi
Investigator Site 512, New Delhi
Investigator Site 504, Pune
Investigator Site 703, Mexico City
Investigator Site 352, Daejeon
Investigator Site 353, Gwangju
Investigator Site 351, Jeollabuk-do
Investigator Site 354, Suwon
Lead Sponsor
Anthera Pharmaceuticals
INDUSTRY